Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    21942930 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Condition: Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Intervention: Drug: Eculizumab
2 Enrolling by invitation The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Conditions: Antibody-mediated Rejection;   Hyperacute Rejection of Cardiac Transplant;   Left Ventricular Dysfunction;   Cardiac Allograft Vasculopathy;   Heart Graft Dysfunction
Intervention: Drug: Eculizumab

Indicates status has not been verified in more than two years